doi:10.3969/j.issn.1673-8640.2018.011.008

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 13

[1]	龚向东,岳晓丽,滕菲,等. 2000-2013年中国梅毒流行特征与趋势分析[J]. 中华皮肤科杂志,2014,47(5):310-315.
[2]	Centers for DiseaseControl and Prevention(CDC). Discordant results from reverse sequence syphilis screening-five laboratories,United States,2006-2010[J]. MMWR Morb Mortal Wkly Rep,2011,60(5):133-137.
[3]	FRENCH P,GOMBERG M,JANIER M,et al.IUSTI:2008 European guidelines on the management of syphilis[J]. Int J STD AIDS,2009,20(5):300-309.
[4]	JANIER M,HEGYI V,DUPIN N,et al.2014 European guideline on the management of syphilis[J]. J Eur Acad Dermatol Venereol,2014,28(12):1581-1593.
[5]	TONG M L,LIN L R,IIU L L,et al.Analysis of 3 algorithms for syphilis serodiagnosis and implications for clinical management[J]. Clin Infect Dis,2014,58(8):1116-1124.
[6]	ROBERTS C.Modelling patterns of agreement for nominal scales[J]. Stat Med,2008,27(6):810-830.
[7]	中华人民共和国卫生部. 预防艾滋病、梅毒和乙肝母婴传播工作实施方案[S]. 2011.
[8]	毛远丽,陈霖. 梅毒检测方法的现状[J]. 中华检验医学杂志,2013,36(10):883-886.
[9]	陈存存,范列英. 抗HCV抗体和抗TP抗体筛查试验的假阳性问题及对策研究进展[J]. 检验医学,2015,30(12):1167-1174.
[10]	WOZNICOVÁ V,VALISOVÁ Z.Performance of CAPTIA SelectSyph-G enzyme-linked immunosorbent assay in syphilis testing of a high-risk population:analysis of discordant results[J]. J Clin Microbiol,2007,45(6):1794-1797.
[11]	HOOVER K W,RADOLF J D.Serodiagnosis of syphilis in the recombinant era:reversal of fortune[J]. J Infect Dis,2011,204(9):1295-1296.
[12]	JANIER M,CHASTANG C,SPINDLER E,et al.A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis[J]. Dermatology,1999,198(4):362-369.
[13]	JONCKHEERE S,BERTH M,VAN ESBROECK M,et al.Evaluation of different confirmatory algorithms using seven treponemal tests on Architect Syphilis TP-positive/RPR-negative sera[J]. Eur J Clin Microbiol Infect Dis,2015,34(10):2041-2048.

患者编号	性别	年龄	临床特征			血清学特征
患者编号	性别	年龄	梅毒史	梅毒治疗	当前诊断	CLIA初筛 S/CO值	第1次血清学结果	与初筛的间隔时间	第2次血清学结果	与初筛的间隔时间
1	男	5 d	无	无	无	1.55			CLIA 0.27	4个月
2	女	9个月	无	无	无	2.51	CLIA 4.21,TPPA阳性,RPR阴性	6个月^*	CLIA 0.14	5个月
3	女	53岁	有	有	宫颈息肉	2.45	CLIA 3.87,TPPA阳性,RPR阴性	2个月
4	女	49岁	有	有	盆腔炎	1.35	CLIA 5.53,TPPA阳性,RPR 1∶16	23个月^*	CLIA 1.21,TPPA阴性,RPR阴性	3个月
5	女	48岁	有	有	子宫肌瘤	1.86			CLIA 1.56,TPPA阳性,RPR阴性	2个月

患者编号	性别	年龄	临床特征			血清学特征
患者编号	性别	年龄	梅毒史	梅毒治疗	当前诊断	CLIA初筛 S/CO值	第1次血清学结果	与初筛的间隔时间	第2次血清学结果	与初筛的间隔时间
1	男	5 d	无	无	无	1.55			CLIA 0.27	4个月
2	女	9个月	无	无	无	2.51	CLIA 4.21,TPPA阳性,RPR阴性	6个月^*	CLIA 0.14	5个月
3	女	53岁	有	有	宫颈息肉	2.45	CLIA 3.87,TPPA阳性,RPR阴性	2个月
4	女	49岁	有	有	盆腔炎	1.35	CLIA 5.53,TPPA阳性,RPR 1∶16	23个月^*	CLIA 1.21,TPPA阴性,RPR阴性	3个月
5	女	48岁	有	有	子宫肌瘤	1.86			CLIA 1.56,TPPA阳性,RPR阴性	2个月

稀释比例	患者1		患者2		患者3		患者4
稀释比例	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA
原倍	5.60	阳性	8.25	阳性	4.53	阳性	3.10	阳性
1∶2	2.66	阳性	3.92	阳性	2.25	阳性	1.23	阳性
1∶4	2.20	阳性	2.18	阳性	1.06	不确定	0.55	阳性
1∶8	1.56	不确定	1.05	阴性	0.52	阴性	0.23	阴性
1∶16	1.01	阴性	0.39	阴性	0.24	阴性	0.07	阴性
1∶32	0.60	阴性	0.19	阴性	0.18	阴性	0.02	阴性

稀释比例	患者1		患者2		患者3		患者4
稀释比例	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA	CLIA （S/CO）值	TPPA
原倍	5.60	阳性	8.25	阳性	4.53	阳性	3.10	阳性
1∶2	2.66	阳性	3.92	阳性	2.25	阳性	1.23	阳性
1∶4	2.20	阳性	2.18	阳性	1.06	不确定	0.55	阳性
1∶8	1.56	不确定	1.05	阴性	0.52	阴性	0.23	阴性
1∶16	1.01	阴性	0.39	阴性	0.24	阴性	0.07	阴性
1∶32	0.60	阴性	0.19	阴性	0.18	阴性	0.02	阴性

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 13

Related Articles 15

Recommended Articles

Metrics